{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:43:51Z","timestamp":1788921831172,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.7759\/cureus.93584","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:50:50Z","timestamp":1759254650000},"source":"Crossref","is-referenced-by-count":2,"title":["Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease and Cancer-Related Anemia: A Narrative Review of Literature"],"prefix":"10.7759","author":[{"given":"Mounica  A","family":"Pothacamuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adwaith","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Chandrashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldyr M","family":"Banderas Echeverry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John  G","family":"Appiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"AlSalami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Alasaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz Zayed","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eziamaka","family":"Mbaekwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Bodapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081884","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors as a new treatment option for anemia in chronic kidney disease","volume":"12","author":"Bartnicki P","year":"2024","unstructured":"Bartnicki P. Hypoxia-inducible factor prolyl hydroxylase inhibitors as a new treatment option for anemia in chronic kidney disease. Biomedicines. 2024, 12:1884. 10.3390\/biomedicines12081884","journal-title":"Biomedicines"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022040413","article-title":"Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs?","volume":"33","author":"Locatelli F","year":"2022","unstructured":"Locatelli F, Del Vecchio L. Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs?. J Am Soc Nephrol. 2022, 33:1966-79. 10.1681\/ASN.2022040413","journal-title":"J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000528443","article-title":"Overall adverse event profile of vadadustat versus darbepoetin alfa for the treatment of anemia associated with chronic kidney disease in phase 3 trials","volume":"53","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Anand S, Eckardt KU, et al.. Overall adverse event profile of vadadustat versus darbepoetin alfa for the treatment of anemia associated with chronic kidney disease in phase 3 trials. Am J Nephrol. 2022, 53:701-10. 10.1159\/000528443","journal-title":"Am J Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.89a.21100","article-title":"Anemia of chronic kidney disease: will new agents deliver on their promise?","volume":"89","author":"Souaid T","year":"2022","unstructured":"Souaid T, Taliercio J, Simon JF, Mehdi A, Nakhoul GN. Anemia of chronic kidney disease: will new agents deliver on their promise?. Cleve Clin J Med. 2022, 89:212-22. 10.3949\/ccjm.89a.21100","journal-title":"Cleve Clin J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2195011","article-title":"The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis","volume":"45","author":"Zhou Q","year":"2023","unstructured":"Zhou Q, Mao M, Li J, Deng F. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2023, 45:2195011. 10.1080\/0886022X.2023.2195011","journal-title":"Ren Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae205","article-title":"Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance","volume":"17","author":"Dasgupta I","year":"2024","unstructured":"Dasgupta I, Bagnis CI, Floris M, et al.. Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance. Clin Kidney J. 2024, 17:sfae205. 10.1093\/ckj\/sfae205","journal-title":"Clin Kidney J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1830371","article-title":"Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary","volume":"13","author":"Musio F","year":"2020","unstructured":"Musio F. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary. Expert Rev Hematol. 2020, 13:1175-88. 10.1080\/17474086.2020.1830371","journal-title":"Expert Rev Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01912-8","article-title":"Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis","volume":"21","author":"Guedes M","year":"2020","unstructured":"Guedes M, Guetter CR, Erbano LH, et al.. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol. 2020, 21:259. 10.1186\/s12882-020-01912-8","journal-title":"BMC Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.08.036","article-title":"Anemia management in cancer patients with chronic kidney disease","volume":"36","author":"Deak AT","year":"2016","unstructured":"Deak AT, Troppan K, Rosenkranz AR. Anemia management in cancer patients with chronic kidney disease. Eur J Intern Med. 2016, 36:13-9. 10.1016\/j.ejim.2016.08.036","journal-title":"Eur J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293980","article-title":"Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: a systematic review and meta-analysis","volume":"18","author":"Karimi Z","year":"2023","unstructured":"Karimi Z, Raeisi Shahraki H, Mohammadian-Hafshejani A. Investigating the relationship between erythropoiesis-stimulating agents and mortality in hemodialysis patients: a systematic review and meta-analysis. PLoS One. 2023, 18:e0293980. 10.1371\/journal.pone.0293980","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15055","article-title":"Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis","volume":"88","author":"Zheng L","year":"2022","unstructured":"Zheng L, Tian J, Liu D, Zhao Y, Fang X, Zhang Y, Liu Y. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022, 88:919-32. 10.1111\/bcp.15055","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-023-02353-x","article-title":"Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials","volume":"27","author":"Yamamoto H","year":"2023","unstructured":"Yamamoto H, Yamada T, Miyazaki K, et al.. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clin Exp Nephrol. 2023, 27:651-9. 10.1007\/s10157-023-02353-x","journal-title":"Clin Exp Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow GM","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YM, et al.. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021, 384:1589-600. 10.1056\/NEJMoa2035938","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013751.pub2","article-title":"Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease","volume":"8","author":"Natale P","year":"2022","unstructured":"Natale P, Palmer SC, Jaure A, et al.. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022, 8:CD013751. 10.1002\/14651858.CD013751.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.02.019","article-title":"The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease","volume":"103","author":"Johansen KL","year":"2023","unstructured":"Johansen KL, Cobitz AR, Singh AK, et al.. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int. 2023, 103:1180-92. 10.1016\/j.kint.2023.02.019","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020050556","article-title":"A randomized trial of strategies using darbepoetin alfa to avoid transfusions in CKD","volume":"32","author":"Toto R","year":"2021","unstructured":"Toto R, Petersen J, Berns JS, Lewis EF, Tran Q, Weir MR. A randomized trial of strategies using darbepoetin alfa to avoid transfusions in CKD. J Am Soc Nephrol. 2021, 32:469-78. 10.1681\/ASN.2020050556","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00550122","article-title":"Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ascend-TD: a phase 3 randomized, double-blind, noninferiority trial","volume":"17","author":"Coyne DW","year":"2022","unstructured":"Coyne DW, Singh AK, Lopes RD, et al.. Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ascend-TD: a phase 3 randomized, double-blind, noninferiority trial. Clin J Am Soc Nephrol. 2022, 17:1325-36. 10.2215\/CJN.00550122","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000531084","article-title":"Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia","volume":"55","author":"Packer M","year":"2024","unstructured":"Packer M. Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia. Am J Nephrol. 2024, 55:255-9. 10.1159\/000531084","journal-title":"Am J Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero M","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024, 6:100851. 10.1016\/j.xkme.2024.100851","journal-title":"Kidney Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.03.020","article-title":"Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension","volume":"78","author":"Pergola PE","year":"2021","unstructured":"Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021, 78:846-56.e1. 10.1053\/j.ajkd.2021.03.020","journal-title":"Am J Kidney Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15291219","article-title":"Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial","volume":"15","author":"Womack R","year":"2020","unstructured":"Womack R, Berru F, Panwar B, Guti\u00e9rrez OM. Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial. Clin J Am Soc Nephrol. 2020, 15:1251-8. 10.2215\/CJN.15291219","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-023-02455-6","article-title":"Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia","volume":"28","author":"Ito K","year":"2024","unstructured":"Ito K, Akizawa T, Arita K, Mitobe Y, Komatsu N. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clin Exp Nephrol. 2024, 28:636-46. 10.1007\/s10157-023-02455-6","journal-title":"Clin Exp Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt JL","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012, 23:1631-4. 10.1681\/ASN.2011111078","journal-title":"J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s J","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021, 8:642296. 10.3389\/fmed.2021.642296","journal-title":"Front Med (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2020.1811121","article-title":"Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients","volume":"42","author":"Wang B","year":"2020","unstructured":"Wang B, Yin Q, Han YC, et al.. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Ren Fail. 2020, 42:912-25. 10.1080\/0886022X.2020.1811121","journal-title":"Ren Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1131516","article-title":"Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis","volume":"14","author":"Yang J","year":"2023","unstructured":"Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis. Front Endocrinol (Lausanne). 2023, 14:1131516. 10.3389\/fendo.2023.1131516","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.795214","article-title":"Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"12","author":"Xiong L","year":"2021","unstructured":"Xiong L, Zhang H, Guo Y, Song Y, Tao Y. Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2021, 12:795214. 10.3389\/fphar.2021.795214","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh AK","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJ, et al.. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021, 385:2313-24. 10.1056\/NEJMoa2113380","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies","volume":"38","author":"Barratt J","year":"2021","unstructured":"Barratt J, Sulowicz W, Sch\u00f6mig M, Esposito C, Reusch M, Young J, Csiky B. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: pooled analysis of four phase 3 studies. Adv Ther. 2021, 38:5345-60. 10.1007\/s12325-021-01903-7","journal-title":"Adv Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2020.05.006","article-title":"Mutual antagonism of hypoxia-inducible factor isoforms in cardiac, vascular, and renal disorders","volume":"5","author":"Packer M","year":"2020","unstructured":"Packer M. Mutual antagonism of hypoxia-inducible factor isoforms in cardiac, vascular, and renal disorders. JACC Basic Transl Sci. 2020, 5:961-8. 10.1016\/j.jacbts.2020.05.006","journal-title":"JACC Basic Transl Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/349374-erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease-and-cancer-related-anemia-a-narrative-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:50:51Z","timestamp":1759254651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/349374-erythropoiesis-stimulating-agents-esas-in-chronic-kidney-disease-and-cancer-related-anemia-a-narrative-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.93584","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}